In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.21590
   PubMed Web of Science ®Google Scholar
• Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4):277–285. doi:10.1016/j.ctrv.2010.02.003
   PubMed Web of Science ®Google Scholar
• Dahlin DC. Pathology of osteosarcoma. Clin Orthop Relat Res. 1975;111(111):23–32. doi:10.1097/00003086-197509000-00004
   Google Scholar
• Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21:vii320–5. doi:10.1093/annonc/mdq276
   PubMed Web of Science ®Google Scholar
• Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5–a population-based study. Lancet Oncol. 2014;15(1):35–47. doi:10.1016/s1470-2045(13)70548-5
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559–568. doi:10.1200/jco.2005.04.063
   PubMed Web of Science ®Google Scholar
• Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res. 2009;152:339–353. doi:10.1007/978-1-4419-0284-9_18
   PubMedGoogle Scholar
• McTiernan A, Jinks RC, Sydes MR, et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer. 2012;48(5):703–712. doi:10.1016/j.ejca.2011.09.012
   PubMed Web of Science ®Google Scholar
• Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47(16):2431–2445. doi:10.1016/j.ejca.2011.05.030
   PubMed Web of Science ®Google Scholar
• Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–532. doi:10.1016/j.ctrv.2013.11.006
   PubMed Web of Science ®Google Scholar
• Carter SK, Blum RH. New Chemotherapeutic Agents. Bleomycin and Adriamycin. CA Cancer J Clin. 1974;24(6):322–331. doi:10.3322/canjclin.24.6.322
   PubMed Web of Science ®Google Scholar
• Pang B, Qiao X, Janssen L, et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nature Communications. 2013;4(1):1908. doi:10.1038/ncomms2921.
   PubMed Web of Science ®Google Scholar
• Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. Doxorubicin-DNA adducts induce a non-topoisomerase II–mediated form of cell death. Cancer Res. 2006;66(9):4863–4871. doi:10.1158/0008-5472.CAN-05-3410.
   PubMed Web of Science ®Google Scholar
• Loehrer PJ. Drugs five years later. Cisplatin. Ann Intern Med. 1984;100(5):704–713. doi:10.7326/0003-4819-100-5-704
   PubMed Web of Science ®Google Scholar
• Hayek ER, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity. New Engl J Med. 2005;352(23):2456–2457. doi:10.1056/NEJM200506093522321.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. The Oncologist. 2006;11(6):694–703. doi:10.1634/theoncologist.11-6-694.
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419–437. doi:10.3322/caac.21204.
   PubMed Web of Science ®Google Scholar
• Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. The Lancet Oncology. 2007;8(9):773–783. doi:10.1016/S1470-2045(07)70245-0
   PubMed Web of Science ®Google Scholar
• Li Y, Yang HY, Lee DS. Advances in biodegradable and injectable hydrogels for biomedical applications. J Control Release. 2021;330:151–160. doi:10.1016/j.jconrel.2020.12.008
   PubMed Web of Science ®Google Scholar
• Ma H, He C, Chen X. Injectable Hydrogels as Local Depots at Tumor Sites for Antitumor Immunotherapy and Immune-Based Combination Therapy. Macromol Biosci. 2021;21(6):e2100039. doi:10.1002/mabi.202100039
   PubMed Web of Science ®Google Scholar
• Rizzo F, Kehr NS. Recent Advances in Injectable Hydrogels for Controlled and Local Drug Delivery. Adv Healthc Mater. 2021;10(1):e2001341. doi:10.1002/adhm.202001341
   PubMed Web of Science ®Google Scholar
• Norouzi M, Nazari B, Miller DW. Injectable hydrogel-based drug delivery systems for local cancer therapy. Drug Discov Today. 2016;21(11):1835–1849. doi:10.1016/j.drudis.2016.07.006
   PubMed Web of Science ®Google Scholar
• Oliva N, Conde J, Wang K, Artzi N. Designing Hydrogels for On-Demand Therapy. Acc Chem Res. 2017;50(4):669–679. doi:10.1021/acs.accounts.6b00536
   PubMed Web of Science ®Google Scholar
• Ma H, He C, Cheng Y, et al. Localized Co-delivery of Doxorubicin, Cisplatin, and Methotrexate by Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment. ACS Appl Mater Interfaces. 2015;7(49):27040–27048. doi:10.1021/acsami.5b09112
   PubMed Web of Science ®Google Scholar
• Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis. 1978;137(2):122–130. doi:10.1093/infdis/137.2.122
   PubMed Web of Science ®Google Scholar
• Ma H, He C, Cheng Y, et al. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment. Biomaterials. 2014;35(30):8723–8734. doi:10.1016/j.biomaterials.2014.06.045
   PubMed Web of Science ®Google Scholar
• Deng H, Dong A, Song J, Chen X. Injectable thermosensitive hydrogel systems based on functional PEG/PCL block polymer for local drug delivery. J Control Release. 2019;297:60–70. doi:10.1016/j.jconrel.2019.01.026
   PubMed Web of Science ®Google Scholar
• Wei P-S, Chen Y-J, Lin S-Y, Chuang K-H, Sheu M-T, Ho H-O. In situ subcutaneously injectable thermosensitive PEG-PLGA diblock and PLGA-PEG-PLGA triblock copolymer composite as sustained delivery of bispecific anti-CD3 scFv T-cell/anti-EGFR Fab Engager (BiTEE). Biomaterials. 2021;278:121166. doi:10.1016/j.biomaterials.2021.121166
   PubMed Web of Science ®Google Scholar
• Park MH, Joo MK, Choi BG, Jeong B. Biodegradable thermogels. Acc Chem Res. 2012;45(3):424–433. doi:10.1021/ar200162j
   PubMed Web of Science ®Google Scholar
• Yu L, Zhang Z, Ding J. Influence of LA and GA sequence in the PLGA block on the properties of thermogelling PLGA-PEG-PLGA block copolymers. Biomacromolecules. 2011;12(4):1290–1297. doi:10.1021/bm101572j
   PubMed Web of Science ®Google Scholar
• Cheng Y, He C, Ding J, Xiao C, Zhuang X, Chen X. Thermosensitive hydrogels based on polypeptides for localized and sustained delivery of anticancer drugs. Biomaterials. 2013;34(38):10338–10347. doi:10.1016/j.biomaterials.2013.09.064
   PubMed Web of Science ®Google Scholar
• Moon HJ, Ko Y, Park MH, Joo MK, Jeong B. Temperature-responsive compounds as in situ gelling biomedical materials. Chem Soc Rev. 2012;41(14):4860–4883. doi:10.1039/c2cs35078e
   PubMed Web of Science ®Google Scholar
• Hu J, Chen Y, Li Y, Zhou Z, Cheng Y. A thermo-degradable hydrogel with light-tunable degradation and drug release. Biomaterials. 2017;112:133–140. doi:10.1016/j.biomaterials.2016.10.015
   PubMed Web of Science ®Google Scholar
• Qiao M, Chen D, Ma X, Liu Y. Injectable biodegradable temperature-responsive PLGA–PEG–PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels. Int J Pharm. 2005;294(1–2):103–112. doi:10.1016/j.ijpharm.2005.01.017
   PubMed Web of Science ®Google Scholar
• Jeong B, Bae YH, Kim SW. Drug release from biodegradable injectable thermosensitive hydrogel of PEG–PLGA–PEG triblock copolymers. J Control Release. 2000;63(1–2):155–163. doi:10.1016/s0168-3659(99)00194-7
   PubMed Web of Science ®Google Scholar
• Yu L, Ci T, Zhou S, Zeng W, Ding J. The thermogelling PLGA–PEG–PLGA block copolymer as a sustained release matrix of doxorubicin. Biomater Sci. 2013;1(4):4. doi:10.1039/c2bm00159d
   Web of Science ®Google Scholar
• Kudawara I, Aoki Y, Ueda T, et al. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a Phase II trial in Japan. J Chemother. 2013;25(1):41–48. doi:10.1179/1973947812y.0000000055
   PubMed Web of Science ®Google Scholar
• Cores EP. Doxorubicin in disseminated osteosarcoma. JAMA. 1972;221(10):1132–1138. doi:10.1001/jama.221.10.1132
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378. doi:10.1016/j.ejphar.2014.07.025
   PubMed Web of Science ®Google Scholar
• Iwamoto Y, Tanaka K. The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 2012;42(6):467–470. doi:10.1093/jjco/hys059
   PubMed Web of Science ®Google Scholar
• Tanaka K, Kawamoto H, Saito I, Yoshimura K, Fukuda H, Iwamoto Y. Preoperative and postoperative chemotherapy with ifosfamide and Adriamycin for adult high-grade soft-tissue sarcomas in the extremities: japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol. 2009;39(4):271–273. doi:10.1093/jjco/hyn153
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Delepine N, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16(2):658–663. doi:10.1200/jco.1998.16.2.658
   PubMed Web of Science ®Google Scholar
• Van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V‐affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998;31(1):1–9. doi:10.1002/(sici)1097-0320(19980101)31:1<::aid-cyto1>3.0.co;2-r
   PubMedGoogle Scholar
• Ow YP, Green DR, Hao Z, Mak TW. Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol. 2008;9(7):532–542. doi:10.1038/nrm2434
   PubMed Web of Science ®Google Scholar
• Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647–656. doi:10.1038/nrc883
   PubMed Web of Science ®Google Scholar
• Cheng EHYA, Wei MC, Weiler S, et al. BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis. Mol Cell. 2001;8(3):705–711. doi:10.1016/S1097-2765(01)00320-3
   PubMed Web of Science ®Google Scholar